The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy.

Anna B Hart, David C Samuels, Todd Hulgan
Author Information
  1. Anna B Hart: Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USA.

Abstract

Mitochondrial toxicity is implicated in some treatment-limiting antiretroviral therapy complications, and reports of mitochondrial dysfunction in untreated HIV infection suggest antiretroviral therapy independent effects of HIV. Several studies have explored associations between mtDNA haplogroups (patterns of mtDNA polymorphisms) and outcomes of HIV infection and/or antiretroviral therapy, but findings have been inconsistent. We systematically reviewed published studies examining mtDNA haplogroups in HIV-infected persons to summarize reported outcome associations, and to highlight potential future research directions. We identified 21 articles published from 2005-2013. Multiple different phenotypes were studied; most were antiretroviral therapy associated metabolic outcomes (e.g. lipodystrophy, insulin resistance, and dyslipidemia). Haplogroup H was associated with the most outcomes, including AIDS progression, CD4 T-cell recovery, cirrhosis (in hepatitis C coinfection), and metabolic outcomes. This review is the first to focus on the emerging area of mtDNA haplogroups in HIV, and summarizes the published literature on associations between mtDNA haplogroups and clinical outcomes in populations of European and African descent. Several reported associations require replication and ideally biological verification before definitive conclusions can be drawn, but research in this area has the potential to explain outcome disparities and impact clinical management of patients.

References

  1. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8739-46 [PMID: 8090716]
  2. Lab Invest. 2001 Jun;81(6):777-90 [PMID: 11406640]
  3. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):111-6 [PMID: 19339895]
  4. Antivir Ther. 2007;12(6):919-29 [PMID: 17926646]
  5. J Med Virol. 2003 Aug;70(4):497-505 [PMID: 12794710]
  6. Science. 2004 Jan 9;303(5655):223-6 [PMID: 14716012]
  7. Am J Gastroenterol. 1999 Aug;94(8):2198-205 [PMID: 10445550]
  8. Eye (Lond). 2003 Apr;17(3):312-7 [PMID: 12724691]
  9. Lancet. 2003 Jul 5;362(9377):22-9 [PMID: 12853195]
  10. AIDS Res Hum Retroviruses. 2013 Oct;29(10):1293-9 [PMID: 23944767]
  11. Ann Hum Genet. 2006 Jul;70(Pt 4):488-95 [PMID: 16759180]
  12. Am J Hum Genet. 2003 Apr;72(4):804-11 [PMID: 12618962]
  13. J Infect Dis. 2005 May 15;191(10):1686-96 [PMID: 15838796]
  14. Hum Genet. 2002 Feb;110(2):130-8 [PMID: 11935318]
  15. Ann Med. 2005;37(3):222-32 [PMID: 16019721]
  16. Am J Hum Genet. 2011 Apr 8;88(4):433-9 [PMID: 21457906]
  17. Clin Ther. 1999 Jul;21(7):1182-92 [PMID: 10463516]
  18. PLoS Med. 2009 Jul 21;6(7):e1000097 [PMID: 19621072]
  19. Circ Res. 2007 Mar 2;100(4):460-73 [PMID: 17332437]
  20. HIV Clin Trials. 2011 Sep-Oct;12(5):277-85 [PMID: 22180526]
  21. FASEB J. 1999 Sep;13(12):1532-6 [PMID: 10463944]
  22. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):451-5 [PMID: 20098332]
  23. J Infect Dis. 2007 Aug 1;196(3):371-6 [PMID: 17597451]
  24. AIDS. 2011 Jan 2;25(1):37-47 [PMID: 20871389]
  25. Lab Invest. 2001 Nov;81(11):1537-44 [PMID: 11706061]
  26. HIV Med. 2006 Jan;7(1):53-8 [PMID: 16313293]
  27. Hum Genet. 2003 Jan;112(1):29-33 [PMID: 12483296]
  28. AIDS Res Hum Retroviruses. 2011 Jul;27(7):777-83 [PMID: 21142587]
  29. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):363-70 [PMID: 21792066]
  30. Clin Genet. 2009 Feb;75(2):163-8 [PMID: 19018796]
  31. PLoS One. 2012;7(8):e43803 [PMID: 22970105]
  32. Trends Pharmacol Sci. 2011 Dec;32(12):715-25 [PMID: 21899897]
  33. Hum Mol Genet. 2010 Sep 1;19(17):3343-53 [PMID: 20566709]
  34. Annu Rev Genet. 2005;39:359-407 [PMID: 16285865]
  35. PLoS One. 2011;6(6):e21595 [PMID: 21747914]
  36. AIDS. 2005 Sep 2;19(13):1341-9 [PMID: 16103764]
  37. PLoS Genet. 2007 Jun;3(6):e104 [PMID: 17604454]
  38. Am J Pathol. 2009 Sep;175(3):927-39 [PMID: 19700756]
  39. HIV Clin Trials. 2011 Jan-Feb;12(1):54-60 [PMID: 21388941]
  40. Diabetes. 2007 Feb;56(2):518-21 [PMID: 17259400]
  41. HIV Med. 2009 Sep;10(8):512-9 [PMID: 19496834]
  42. Nat Med. 1995 May;1(5):417-22 [PMID: 7585087]
  43. Environ Mol Mutagen. 2007 Apr-May;48(3-4):215-23 [PMID: 16395695]
  44. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):113-20 [PMID: 22245716]
  45. AIDS. 2008 Nov 30;22(18):2429-39 [PMID: 19005266]
  46. Hum Mutat. 2009 Feb;30(2):E386-94 [PMID: 18853457]
  47. Genetics. 2006 Jan;172(1):373-87 [PMID: 16172508]
  48. J Pharmacol Exp Ther. 1997 Mar;280(3):1228-34 [PMID: 9067308]
  49. AIDS. 2002 Nov 8;16(16):2105-17 [PMID: 12409731]
  50. Nature. 2001 Dec 13;414(6865):807-12 [PMID: 11742413]
  51. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):371-8 [PMID: 21792063]
  52. J Infect Dis. 2011 Mar 1;203(5):620-4 [PMID: 21227914]
  53. N Engl J Med. 2005 Jan 6;352(1):48-62 [PMID: 15635112]
  54. AIDS. 2011 Aug 24;25(13):1619-926 [PMID: 21673559]
  55. Nat Rev Endocrinol. 2011 Sep 13;8(2):92-103 [PMID: 21912398]
  56. Clin Infect Dis. 2001 Aug 15;33(4):562-9 [PMID: 11462196]
  57. Genetics. 1996 Dec;144(4):1835-50 [PMID: 8978068]
  58. J Antimicrob Chemother. 2013 Oct;68(10):2349-57 [PMID: 23749950]
  59. Am J Ophthalmol. 2006 Aug;142(2):284-92 [PMID: 16876510]
  60. AIDS. 2005 Oct 14;19(15):1627-33 [PMID: 16184032]
  61. Blood. 2000 Jul 15;96(2):740-6 [PMID: 10887143]
  62. AIDS. 1998 Oct 1;12(14):1735-44 [PMID: 9792373]
  63. Int J Cardiol. 2006 Sep 20;112(2):202-6 [PMID: 16313983]
  64. Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):171-6 [PMID: 12509511]
  65. Curr Pharm Des. 2010 Oct;16(30):3339-51 [PMID: 20687890]
  66. BMC Med Genet. 2009 Jun 18;10:60 [PMID: 19534826]
  67. J Neurovirol. 2012 Dec;18(6):511-20 [PMID: 23073667]
  68. Am J Hum Genet. 1997 May;60(5):1107-21 [PMID: 9150158]
  69. Clin Infect Dis. 2008 Oct 1;47(7):962-8 [PMID: 18752438]
  70. Clin Infect Dis. 2010 Oct 15;51(8):937-46 [PMID: 20839968]
  71. Curr Opin Investig Drugs. 2005 Nov;6(11):1095-102 [PMID: 16312129]
  72. Am J Hum Genet. 2007 Apr;80(4):605-15 [PMID: 17357068]
  73. Blood. 2007 Mar 15;109(6):2505-13 [PMID: 17095625]
  74. J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):381-8 [PMID: 18614930]
  75. Circ Res. 2010 Oct 15;107(8):1021-31 [PMID: 20705925]
  76. Expert Opin Drug Saf. 2010 Jul;9(4):545-59 [PMID: 20384533]
  77. J Infect Dis. 2010 Jun 1;201(11):1703-7 [PMID: 20402593]
  78. AIDS Res Hum Retroviruses. 2013 Jul;29(7):1031-9 [PMID: 23428049]
  79. J Infect Dis. 2008 Mar 15;197(6):858-66 [PMID: 18419350]
  80. Am J Hum Genet. 2002 May;70(5):1152-71 [PMID: 11938495]
  81. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):178-83 [PMID: 23666137]
  82. Antivir Ther. 2005;10 Suppl 2:M29-45 [PMID: 16152704]
  83. J Atheroscler Thromb. 2011;18(2):166-75 [PMID: 21099167]
  84. Am J Hum Genet. 2006 Jul;79(1):54-61 [PMID: 16773565]
  85. Circulation. 2008 May 13;117(19):2492-501 [PMID: 18458168]
  86. Antivir Ther. 2012;17(2):275-82 [PMID: 22293466]
  87. Am J Hum Genet. 2007 Mar;80(3):407-15 [PMID: 17273962]

Grants

  1. R01 MH095621/NIMH NIH HHS
  2. R03 DA029506/NIDA NIH HHS
  3. MH095621/NIMH NIH HHS
  4. DA029506/NIDA NIH HHS

MeSH Term

Anti-HIV Agents
Antiretroviral Therapy, Highly Active
DNA, Mitochondrial
Genome, Viral
HIV Infections
HIV-1
Haplotypes
Humans
Phylogeny
Polymorphism, Genetic

Chemicals

Anti-HIV Agents
DNA, Mitochondrial

Word Cloud

Created with Highcharts 10.0.0outcomesantiretroviraltherapyHIVmtDNAhaplogroupsassociationsinfectionstudiespublishedmitochondrialSeveralreportedoutcomepotentialresearchassociatedmetabolicreviewareaclinicalMitochondrialtoxicityimplicatedtreatment-limitingcomplicationsreportsdysfunctionuntreatedsuggestindependenteffectsexploredpatternspolymorphismsand/orfindingsinconsistentsystematicallyreviewedexaminingHIV-infectedpersonssummarizehighlightfuturedirectionsidentified21articles2005-2013MultipledifferentphenotypesstudiedeglipodystrophyinsulinresistancedyslipidemiaHaplogroupHincludingAIDSprogressionCD4T-cellrecoverycirrhosishepatitisCcoinfectionfirstfocusemergingsummarizesliteraturepopulationsEuropeanAfricandescentrequirereplicationideallybiologicalverificationdefinitiveconclusionscandrawnexplaindisparitiesimpactmanagementpatientsgenome:systematicDNA

Similar Articles

Cited By